Myriad Genetics

Myriad Genetics is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. At the end of fiscal year 2015, Myriad had annual revenue of approximately $723.1 million and 2,038 employees, Myriad is the global leader and pioneer in the molecular diagnostics field with twelve innovative diagnostic products. Through our proprietary technologies, we believe we are positioned to identify important disease genes, the proteins they produce, and the biological pathways in which they are involved to better understand the genetic basis of human disease and the role that genes and their related proteins may play in the disease process.

Type
Public
HQ
Salt Lake City, US
Founded
1992
Size (employees)
2,206 (est)+9%
Website
myriad.com
Myriad Genetics was founded in 1992 and is headquartered in Salt Lake City, US

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, Austin, Zürich, South San Francisco
Salt Lake City, US (HQ)
320 Wakara Way
South San Francisco, US
341 Oyster Point Blvd
Zürich, CH
95 Leutschenbachstrasse
Austin, US
3300 Duval Rd

Myriad Genetics Metrics

Myriad Genetics Financial Metrics

Revenue (2016)

$753.8 m

Revenue growth (2015-16), %

4%

Gross profit

$621 m

Gross profit margin (2016), %

82%

Net income (2016)

$125.3 m

Market capitalization (21-Mar-2017)

$1.3 b

Closing share price (21-Mar-2017)

$19.1

Cash (30-Jun-2016)

$68.5 m
Myriad Genetics's current market capitalization is $1.3 b.
Myriad Genetics's revenue was reported to be $753.8 m in FY, 2016 which is a 4.2% increase from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$778.2 m$723.1 m$753.8 m

Revenue growth, %

(7%)4%

Gross profit

$682.1 m$590.3 m$621 m

Gross profit Margin, %

88%82%82%

Operating expense total

$407.6 m$456.1 m$454.2 m

EBIT

$274.4 m$134.2 m$166.8 m

EBIT margin, %

35%19%22%

Interest income

$5.4 m$400 k$900 k

Pre tax profit

$277.9 m$134.9 m$168.9 m

Income tax expense

$101.6 m$54.7 m$43.6 m

Net Income

$176.2 m$80.2 m$125.3 m
FY, 2014FY, 2015FY, 2016

Cash

$64.8 m$64.1 m$68.5 m

Accounts Receivable

$3.8 m$1.9 m$3.3 m

Inventories

$23.9 m$25.1 m$38.3 m

Current Assets

$322.4 m$283.6 m$314.5 m

PP&E

$67.2 m$58.3 m

Goodwill

$169.2 m$177.2 m$195.3 m

Total Assets

$823.8 m$766.2 m$880.5 m

Accounts Payable

$23.1 m$21.1 m$21.1 m

Current Liabilities

$80.6 m$68.7 m$72.3 m

Additional Paid-in Capital

$717.8 m$745.4 m$830.1 m

Retained Earnings

$2 m($77 m)($73.2 m)

Total Equity

$719 m$662.1 m$748.1 m

Financial Leverage

1.1 x1.2 x1.2 x
FY, 2014FY, 2015FY, 2016

Net Income

$176.2 m$80.2 m$125.3 m

Depreciation and Amortization

$13.8 m$25 m$26.7 m

Accounts Receivable

($1.9 m)$2.5 m($900 k)

Inventories

($16 m)($800 k)($15 m)

Accounts Payable

($1.5 m)($3.1 m)($3.1 m)

Cash From Operating Activities

$190.2 m$140.5 m$166.3 m

Capital Expenditures

($23.9 m)($5 m)

Cash From Investing Activities

($17.7 m)($91.4 m)

Income Taxes Paid

$108.2 m

Free Cash Flow

$164.4 m$171.3 m

Myriad Genetics Market Value History

Myriad Genetics Online Presence

Myriad Genetics News

Myriad Genetics Company Life

You may also be interested in